### ü´Å Pulmonary Medicine: Bullous Lung Disease on Chest CT

#### ‚úÖ True Statements
1. **Bullous lung disease** is most commonly caused by **cigarette use**.
2. On **chest computed tomography (CT)**, **bullae** appear as **hyperlucent areas** that are **sharply demarcated from surrounding lung** by a **thin wall**.
3. **Bullae** may cause **compressive atelectasis** of adjacent lung tissue.
4. Large **bullae** can produce a **mediastinal shift**.
5. **Bullae** may represent **severe localized disease** or be associated with **widespread emphysema**.
6. **Bullectomy** may be a treatment option for **patients with localized bullous lung disease**.

#### üí¨ Extra
2. Hyperlucency on CT reflects absence of normal lung tissue within the bullae.
3. Compressive atelectasis refers to collapse of surrounding normal lung due to external pressure from bullae.
4. Mediastinal shift may be seen radiographically when bullae enlarge enough to displace mediastinal structures.

#### üè∑Ô∏è Tags
#Pulmonology #UrgentCare #EmergentCare #BullousLungDisease #ChestCT #Bullectomy

#### üìö Reference
MKSAP 19: Pulmonary Medicine. American College of Physicians.

#### üÜî Question ID
PMVDX24021

#### üïí Last Updated
February 2025

---

#### üñºÔ∏è Supplemental Figures
<figure>
  <img src="Identify bullae on chest CT.jpg" alt="Identify bullae on chest CT.jpg">
  <figcaption><strong>Figure: Identify bullae on chest CT</strong>.</figcaption>
</figure>

---

#### üìñ Related Text
MKSAP 19: Pulmonary Medicine ‚Äî Airways Disease, Chronic Obstructive Pulmonary Disease, Chronic Obstructive Pulmonary Disease

---

### üìò Related Text Derivations

#### ‚úÖ True Statements ‚Äî Epidemiology of COPD
1. **Chronic obstructive pulmonary disease (COPD)** is a chronic lung disease defined by chronic respiratory symptoms due to airway abnormalities that cause persistent airflow obstruction.  
2. **Chronic obstructive pulmonary disease (COPD)** affects more than 6% of the U.S. population and approximately 10% of the global population.  
3. **Chronic obstructive pulmonary disease (COPD)** is associated with high morbidity and mortality and is the sixth leading cause of death in the United States.  
4. The **World Health Organization (WHO)** predicts that by 2030, COPD will be the fifth most prevalent disorder and the third leading cause of death worldwide.  

---

#### ‚úÖ True Statements ‚Äî Pathophysiology of COPD
1. **Chronic obstructive pulmonary disease (COPD)** is an inflammatory condition triggered by cigarette smoke and other irritants that activate macrophages and epithelial cells within the respiratory tract.  
2. In **chronic obstructive pulmonary disease (COPD)**, epithelial cells release neutrophil chemotactic factors, and macrophages and recruited neutrophils release proteases that destroy lung parenchyma.  
3. In **chronic obstructive pulmonary disease (COPD)**, proteases are normally inactivated by antiproteases such as **Œ±1-antitrypsin**, but protease levels are increased.  
4. In **chronic obstructive pulmonary disease (COPD)**, oxidative stress from irritants and inflammatory cells contributes to additional inflammation and tissue destruction.  
5. **Chronic obstructive pulmonary disease (COPD)** causes fibrosis of the small airways, reduced elastic recoil of the lungs, static hyperinflation, and abnormally elevated mucin concentrations.  
6. In **chronic obstructive pulmonary disease (COPD)**, increasing airway inflammation worsens airflow obstruction, reduces the ability to exhale fully, and produces dynamic hyperinflation (air trapping).  
7. In **chronic obstructive pulmonary disease (COPD)**, hyperinflation appears radiographically as an increased anteroposterior chest diameter and flattening of the diaphragm.  
8. In **chronic obstructive pulmonary disease (COPD)**, diaphragmatic flattening limits the ability to increase breath volume during exertion.  
9. In **chronic obstructive pulmonary disease (COPD)**, compensatory use of accessory muscles and an increased respiratory rate augment minute ventilation, increase the work of breathing, and contribute to dyspnea.  

#### üí¨ Extra ‚Äî Pathophysiology of COPD
6. Dynamic hyperinflation occurs when inhalation begins before exhalation is completed.  

---

#### ‚úÖ True Statements ‚Äî Risk Factors for COPD
1. **Cigarette smoke exposure**, including secondhand exposure, is the most important U.S. risk factor for **chronic obstructive pulmonary disease (COPD)**.  
2. Nonsmoking risk factors contribute to more than 50% of the global burden of **chronic obstructive pulmonary disease (COPD)**.  
3. Genetic predisposition influences susceptibility to **chronic obstructive pulmonary disease (COPD)** among smokers.  
4. Long-term exposure to **air pollution** (indoor and outdoor) and to **occupational chemicals and dusts** increases risk for **chronic obstructive pulmonary disease (COPD)**.  
5. Indoor biomass fuel exposure, such as wood used for cooking, is a common risk factor for **chronic obstructive pulmonary disease (COPD)** in some regions.  
6. **Family history of COPD** and **Œ±1-antitrypsin deficiency** are additional risk factors for **chronic obstructive pulmonary disease (COPD)**.  

---

#### ‚úÖ True Statements ‚Äî Heterogeneity of COPD
1. **Chronic obstructive pulmonary disease (COPD)** is heterogeneous, with some patients presenting predominantly with chronic productive cough from mucus hypersecretion and others with progressive dyspnea from hyperinflation.  
2. Variable symptoms of **chronic obstructive pulmonary disease (COPD)** include nonproductive cough, chest tightness, wheezing, and fatigue.  
3. Phenotypic heterogeneity of **chronic obstructive pulmonary disease (COPD)** has been characterized by clinical, physiologic, molecular, and radiographic variables.  
4. Eosinophilia in **chronic obstructive pulmonary disease (COPD)** is associated with increased responsiveness to glucocorticoids.  
5. A subgroup of patients with **chronic obstructive pulmonary disease (COPD)** is prone to frequent acute exacerbations.  
6. The **BODE index** (Body mass index, airflow Obstruction, Dyspnea, Exercise capacity) is used to aid prognosis and treatment decisions in **chronic obstructive pulmonary disease (COPD)**.  
7. In the **BODE index**, airflow obstruction is measured by postbronchodilator FEV‚ÇÅ % predicted, dyspnea is graded by the modified Medical Research Council (mMRC) Dyspnea Scale, and exercise capacity is measured by the 6-minute walk distance.  
8. The **BODE index** provides better prognostic information than FEV‚ÇÅ alone in **chronic obstructive pulmonary disease (COPD)** and approximates 4-year survival and hospitalization risk.  

---

#### ‚úÖ True Statements ‚Äî Comorbid Conditions Associated With COPD
1. Patients with **chronic obstructive pulmonary disease (COPD)** frequently have comorbid conditions that increase morbidity and mortality.  
2. **Cardiovascular disease** and **lung cancer** share common risk factors with **chronic obstructive pulmonary disease (COPD)**.  
3. Comorbidities such as sarcopenia, weight loss, osteoporosis, and depression are independently associated with **chronic obstructive pulmonary disease (COPD)** or consequences of its treatment.  

---

#### ‚úÖ True Statements ‚Äî Diagnosis of COPD
1. **Chronic obstructive pulmonary disease (COPD)** should be considered and spirometry performed in patients with progressive dyspnea, chronic cough with or without sputum, or recurrent lower respiratory tract infections, particularly in the presence of risk factors.  
2. Screening spirometry in asymptomatic adults is not recommended by the **U.S. Preventive Services Task Force**, whereas the **Global Initiative for Chronic Obstructive Lung Disease (GOLD)** recommends screening in individuals with risk factors.  
3. The diagnosis of **chronic obstructive pulmonary disease (COPD)** is confirmed by postbronchodilator **FEV‚ÇÅ/FVC <0.70** on spirometry.  
4. **Asthma** is differentiated from **chronic obstructive pulmonary disease (COPD)** by reversible airflow obstruction with bronchodilator therapy.  
5. Lung volumes and diffusing capacity testing are not required for the diagnosis of **chronic obstructive pulmonary disease (COPD)** but may help determine severity.  
6. Other causes of chronic respiratory symptoms that should be excluded when diagnosing **chronic obstructive pulmonary disease (COPD)** include heart failure, bronchiectasis, obliterative bronchiolitis, tuberculosis, and diffuse panbronchiolitis.  

---

#### ‚úÖ True Statements ‚Äî COPD Disease Assessment
1. Assessment of **chronic obstructive pulmonary disease (COPD)** involves determining symptom severity and risk of acute exacerbation.  
2. Symptom severity in **chronic obstructive pulmonary disease (COPD)** can be assessed with validated tools, including the COPD Assessment Test (CAT), the modified Medical Research Council (mMRC) scale, the St. George‚Äôs Respiratory Questionnaire, and the Clinical COPD Questionnaire.  
3. Predictors of high risk for recurrent exacerbations in **chronic obstructive pulmonary disease (COPD)** include FEV‚ÇÅ <50% predicted, two or more exacerbations in the past year, or prior hospitalization for an exacerbation.  
4. The **GOLD model** for **chronic obstructive pulmonary disease (COPD)** combines symptom scores and exacerbation history to classify disease severity.  
5. The COPD Assessment Test (CAT) score ranges from 0 to 40, with higher scores indicating greater symptom severity in **chronic obstructive pulmonary disease (COPD)**.  
6. Spirometric airflow obstruction and comorbid conditions are additional markers of severity in **chronic obstructive pulmonary disease (COPD)**.  
7. Identifying comorbidities is important because they increase morbidity and mortality in **chronic obstructive pulmonary disease (COPD)**.  
8. Pulse oximetry at rest and exertion is used in **chronic obstructive pulmonary disease (COPD)** to determine need for supplemental oxygen.  
9. Arterial blood gases should be measured in **chronic obstructive pulmonary disease (COPD)** patients with low FEV‚ÇÅ, altered mental status, acute exacerbation, elevated bicarbonate, or oxygen saturation <92%.  
10. An **Œ±1-antitrypsin level** should be measured once in all patients with **chronic obstructive pulmonary disease (COPD)**.  
11. Basilar emphysema, associated liver disease or panniculitis, or a strong family history of emphysema suggests possible **Œ±1-antitrypsin deficiency** in **chronic obstructive pulmonary disease (COPD)**, but testing is required because these features are not sensitive enough to rule it out.  

---

#### ‚úÖ True Statements ‚Äî Management of COPD
1. Management of **chronic obstructive pulmonary disease (COPD)** requires identifying and reversing risk factors, especially ongoing exposure to cigarette smoke.  
2. In **chronic obstructive pulmonary disease (COPD)**, therapy should be guided by disease severity and patients should be monitored for progression.  
3. The goals of treatment in **chronic obstructive pulmonary disease (COPD)** are to reduce symptoms, improve exercise tolerance, improve quality of life, prevent and treat exacerbations, prevent disease progression, and reduce mortality.  

---

#### ‚úÖ True Statements ‚Äî Smoking Cessation and COPD
1. **Smoking cessation** is the most important intervention in **chronic obstructive pulmonary disease (COPD)** because it slows the decline of FEV‚ÇÅ.  
2. In **chronic obstructive pulmonary disease (COPD)**, success rates for smoking cessation increase when counseling is combined with medication therapy.  
3. All smokers with **chronic obstructive pulmonary disease (COPD)** without contraindications should be offered at least one FDA-approved pharmacologic treatment for smoking cessation.  

---

#### ‚úÖ True Statements ‚Äî Pharmacologic Therapy for COPD
1. Pharmacologic therapy in **chronic obstructive pulmonary disease (COPD)** reduces symptoms, improves quality of life, and decreases the frequency and severity of exacerbations.  
2. **Bronchodilators** are the cornerstone of pharmacologic therapy in **chronic obstructive pulmonary disease (COPD)** regardless of severity.  
3. Every time inhaled therapy is prescribed in **chronic obstructive pulmonary disease (COPD)**, clinicians should provide education on proper inhaler technique.  
4. Initial pharmacologic management of **chronic obstructive pulmonary disease (COPD)** is guided by GOLD patient-group recommendations.  

---

#### ‚úÖ True Statements ‚Äî Bronchodilators
1. Inhaled bronchodilators for **chronic obstructive pulmonary disease (COPD)** include Œ≤‚ÇÇ-agonists and antimuscarinic agents, which are available in both short-acting and long-acting forms.  
2. Short-acting Œ≤‚ÇÇ-agonists and short-acting muscarinic antagonists provide similar bronchodilation in **chronic obstructive pulmonary disease (COPD)** and can be used as monotherapy.  
3. Dual therapy with a short-acting Œ≤‚ÇÇ-agonist and a short-acting muscarinic antagonist provides greater bronchodilation and airflow improvement in some patients with **chronic obstructive pulmonary disease (COPD)**.  
4. In patients with **chronic obstructive pulmonary disease (COPD)** and more severe disease not controlled with short-acting agents, a long-acting bronchodilator (LABA or LAMA) should be prescribed.  
5. If symptoms persist in **chronic obstructive pulmonary disease (COPD)** despite monotherapy with a long-acting bronchodilator, adding a second long-acting agent from the alternate class may improve outcomes.  
6. Long-acting bronchodilator monotherapy should not be used in patients with **chronic obstructive pulmonary disease (COPD) and asthma**, unless an inhaled glucocorticoid is also prescribed, because LABA monotherapy increases mortality risk in asthma.  

---

#### ‚úÖ True Statements ‚Äî Inhaled Corticosteroids (Glucocorticoids)
1. Inhaled glucocorticoids in **chronic obstructive pulmonary disease (COPD)** are typically prescribed only in combination with a long-acting bronchodilator.  
2. Inhaled glucocorticoids are generally not used as monotherapy in **chronic obstructive pulmonary disease (COPD)** unless the patient cannot tolerate long-acting bronchodilators.  
3. Inhaled glucocorticoids increase the risk of pneumonia in **chronic obstructive pulmonary disease (COPD)** but improve lung function, reduce symptoms, and decrease exacerbations in moderate to severe disease.  
4. Triple therapy with a LABA, a LAMA, and an inhaled glucocorticoid improves symptoms, reduces exacerbations, and decreases mortality when delivered as a single inhaler in patients with severe **chronic obstructive pulmonary disease (COPD)**.  
5. Inhaled glucocorticoids should be added to long-acting bronchodilators in **chronic obstructive pulmonary disease (COPD)** if the blood eosinophil count exceeds 300/¬µL or if significant asthmatic features are present.  

---

#### ‚úÖ True Statements ‚Äî Oral Glucocorticoids
1. Oral glucocorticoids are recommended for short courses in the treatment of acute exacerbations of **chronic obstructive pulmonary disease (COPD)**.  
2. Long-term oral glucocorticoid therapy should be avoided in **chronic obstructive pulmonary disease (COPD)** because of adverse effects, including diabetes and osteoporosis.  

---

#### ‚úÖ True Statements ‚Äî Methylxanthines
1. Methylxanthines such as aminophylline and theophylline are rarely used in the treatment of **chronic obstructive pulmonary disease (COPD)**.  
2. Theophylline may improve functional capacity and reduce exacerbations in advanced **chronic obstructive pulmonary disease (COPD)** but has a narrow therapeutic window.  
3. Aminophylline and theophylline have not demonstrated benefit during acute exacerbations of **chronic obstructive pulmonary disease (COPD)**.  

---

#### ‚úÖ True Statements ‚Äî Roflumilast
1. Roflumilast is a selective phosphodiesterase-4 inhibitor that reduces exacerbation frequency in severe **chronic obstructive pulmonary disease (COPD)** with FEV‚ÇÅ <50% predicted and chronic bronchitis symptoms.  
2. Roflumilast should be considered in patients with **chronic obstructive pulmonary disease (COPD)** who have at least two exacerbations or one hospitalization for an exacerbation in the prior year.  

---

#### ‚úÖ True Statements ‚Äî Œ±1-Antitrypsin Augmentation Therapy
1. Antiproteases such as Œ±1-antitrypsin normally inactivate proteases that cause lung damage.  
2. In patients with **chronic obstructive pulmonary disease (COPD)** due to Œ±1-antitrypsin deficiency, augmentation therapy with Œ±1-antitrypsin may slow the progression of emphysema.  
3. Œ±1-Antitrypsin augmentation therapy has not been conclusively shown to decrease exacerbations or reduce the rate of FEV‚ÇÅ decline in **chronic obstructive pulmonary disease (COPD)**.  
4. Œ±1-Antitrypsin augmentation therapy is ineffective in **chronic obstructive pulmonary disease (COPD)** not caused by Œ±1-antitrypsin deficiency.  

---

#### ‚úÖ True Statements ‚Äî Other Agents
1. Long-term macrolide therapy may reduce exacerbation frequency in severe **chronic obstructive pulmonary disease (COPD)** with frequent prior exacerbations.  
2. Mucolytics and antitussives are not routinely recommended for **chronic obstructive pulmonary disease (COPD)** but may relieve symptoms in patients with significant sputum production.  
3. Dupilumab may be added to inhaled glucocorticoids and long-acting bronchodilators in **chronic obstructive pulmonary disease (COPD)** patients with chronic bronchitis and high eosinophil counts.  
4. Ensifentrine, a phosphodiesterase inhibitor, improves lung function and may reduce exacerbations in **chronic obstructive pulmonary disease (COPD)**, though it has not demonstrated improvement in quality of life.  

---

#### ‚úÖ True Statements ‚Äî Immunization
1. Respiratory infections are the most common trigger of exacerbations in **chronic obstructive pulmonary disease (COPD)**.  
2. Routine immunizations are recommended for all patients with **chronic obstructive pulmonary disease (COPD)** to reduce infection risk.  
3. Recommended vaccines for patients with **chronic obstructive pulmonary disease (COPD)** include influenza, COVID-19, respiratory syncytial virus, tetanus-diphtheria-acellular pertussis, zoster for adults ‚â•50 years, and pneumococcal vaccines.  

---

#### ‚úÖ True Statements ‚Äî Nonpharmacologic Therapy for COPD: Pulmonary Rehabilitation
1. **Pulmonary rehabilitation** is a comprehensive program that includes **exercise training**, **nutritional support**, **education**, and **social support** for **chronic obstructive pulmonary disease (COPD)**.
2. **Pulmonary rehabilitation** reduces **symptoms** in **chronic obstructive pulmonary disease (COPD)**.
3. **Pulmonary rehabilitation** improves **quality of life** in **chronic obstructive pulmonary disease (COPD)**.
4. **Pulmonary rehabilitation** decreases the **frequency of hospitalizations** in **chronic obstructive pulmonary disease (COPD)**.
5. **Pulmonary rehabilitation** should be **added to medical therapy** after a **recent COPD exacerbation**.
6. **Pulmonary rehabilitation** should be **added to medical therapy** for **GOLD group B** or **GOLD group E** **chronic obstructive pulmonary disease (COPD)**.

#### üí¨ Extra ‚Äî Pulmonary Rehabilitation
1. The program components (exercise, nutrition, education, social support) are delivered as a coordinated intervention.

---

#### ‚úÖ True Statements ‚Äî Nonpharmacologic Therapy for COPD: Oxygen Therapy
1. **Supplemental oxygen** improves **quality of life** and **decreases mortality** in **chronic obstructive pulmonary disease (COPD)** with **resting hypoxemia** defined as **PaO‚ÇÇ ‚â§55 mm Hg** or **SpO‚ÇÇ ‚â§88%** by pulse oximetry.
2. **Supplemental oxygen** should be **offered** in **chronic obstructive pulmonary disease (COPD)** when **PaO‚ÇÇ ‚â§59 mm Hg** or **SpO‚ÇÇ ‚â§89%** in the presence of **cor pulmonale**, **heart failure**, or **erythrocytosis**.
3. **Supplemental oxygen** is commonly prescribed in **chronic obstructive pulmonary disease (COPD)** when **SpO‚ÇÇ <89%** during **sleep**, **exertion**, or **air travel**, although **benefits are less defined** in these contexts.

---

#### ‚úÖ True Statements ‚Äî Nonpharmacologic Therapy for COPD: Noninvasive Positive-Pressure Ventilation
1. **Noninvasive positive-pressure ventilation (noninvasive PPV)** can be used for **acute** and **chronic respiratory failure** in **chronic obstructive pulmonary disease (COPD)**.
2. In **acute hypercapnic respiratory failure with acidosis** from a **COPD exacerbation**, **noninvasive PPV** **improves symptoms** and **reduces** **intubation**, **length of hospital stay**, and **mortality**.
3. **Noninvasive PPV** may be **beneficial for palliative care** in **chronic obstructive pulmonary disease (COPD)**.
4. **Noninvasive PPV** may **aid discontinuation of mechanical ventilation** in **chronic obstructive pulmonary disease (COPD) with pneumonia**.
5. **Noninvasive PPV** does **not replace intubation** and **mechanical ventilation** in **critically ill**, **comatose**, or **cardiac arrest** patients with **chronic obstructive pulmonary disease (COPD)**.
6. Adding **home noninvasive PPV** to **oxygen therapy** in **chronic obstructive pulmonary disease (COPD)** with **chronic hypercapnic respiratory failure** (**PaCO‚ÇÇ ‚â•52 mm Hg [6.9 kPa]**) **after an acute exacerbation** **prolongs time** to **readmission** and **death**.
7. **Improvement of pH and PaCO‚ÇÇ within 1‚Äì2 hours** of starting **noninvasive PPV** **predicts success** in **chronic obstructive pulmonary disease (COPD)**.

---

#### ‚úÖ True Statements ‚Äî Lung Volume Reduction Therapy
1. **Lung volume reduction surgery** improves **quality of life**, **exercise tolerance**, **pulmonary function**, and **survival** in **upper-lobe‚Äìpredominant emphysema** with **significant exercise limitation** that **persists after pulmonary rehabilitation** in **chronic obstructive pulmonary disease (COPD)**.
2. **Lung volume reduction surgery** should **not** be offered in **chronic obstructive pulmonary disease (COPD)** with **FEV‚ÇÅ <20% predicted** because of **high operative mortality**.
3. **Lung volume reduction surgery** should **not** be offered in **chronic obstructive pulmonary disease (COPD)** with **diffusing capacity <20% predicted** because of **high operative mortality**.
4. **Lung volume reduction surgery** should **not** be offered in **non‚Äìupper-lobe‚Äìpredominant disease** because of **high operative mortality**.
5. **Endoscopic lung volume reduction** techniques (**endobronchial valves or plugs**, **thermal airway ablation**) are **under study** for emphysema in **chronic obstructive pulmonary disease (COPD)**.
6. **Severe air trapping** and **hyperinflation** may confer the **most benefit** from **endoscopic lung volume reduction** in **chronic obstructive pulmonary disease (COPD)**.
7. **Patient selection** for **endoscopic techniques** in **chronic obstructive pulmonary disease (COPD)** is **complex** and **procedure-specific**.

---

#### ‚úÖ True Statements ‚Äî Lung Transplantation
1. **Lung transplantation** improves **quality of life** in **severe chronic obstructive pulmonary disease (COPD)**.
2. The **median life expectancy** after **lung transplantation** for **chronic obstructive pulmonary disease (COPD)** is **5.9 years**.
3. **Referral for lung transplantation** in **chronic obstructive pulmonary disease (COPD)** should consider **life expectancy**, **quality of life**, and **patient preferences**.
4. **Lung transplantation candidates** in **chronic obstructive pulmonary disease (COPD)** generally have **high risk of death within <2 years** and a **high probability of 90-day postoperative survival**.
5. **Referral for evaluation** for **lung transplantation** in **chronic obstructive pulmonary disease (COPD)** is appropriate with any of the following: **BODE index 5‚Äì6**, **resting hypoxemia**, **hypercapnia**, **FEV‚ÇÅ <25% predicted**, or **significant exercise limitation** despite **optimal therapy**, **smoking cessation**, and **pulmonary rehabilitation**.

---

#### ‚úÖ True Statements ‚Äî Prognosis of COPD and Goals of Care
1. The **GOLD initiative** classifies **chronic obstructive pulmonary disease (COPD)** severity using **post-bronchodilator FEV‚ÇÅ**, **exacerbation number**, and **symptoms** to guide **treatment escalation or de-escalation**.
2. The **BODE index** (Body mass index, airflow **Obstruction**, **Dyspnea**, **Exercise** capacity) approximates **4-year survival** in **chronic obstructive pulmonary disease (COPD)**.
3. **Palliative care** can **reduce symptom burden** in **advanced chronic obstructive pulmonary disease (COPD)** or **poor overall prognosis**.
4. **Palliative care** in **chronic obstructive pulmonary disease (COPD)** helps manage **dyspnea**, **anxiety**, and **depression** at **any disease stage**.
5. **Opioids** are **commonly used** for **refractory dyspnea** in **chronic obstructive pulmonary disease (COPD)**.
6. **Hospice care** may be considered in **severe chronic obstructive pulmonary disease (COPD)** with **disabling symptoms despite therapy**, **progressive disease** (for example, **increasing emergency department visits or hospitalizations**), or **hypoxemia** or **hypercapnia**.

---

#### ‚úÖ True Statements ‚Äî Definition of COPD Exacerbation
1. An **acute chronic obstructive pulmonary disease (COPD) exacerbation** is **worsening of usual respiratory symptoms within <14 days**, often with **local or systemic inflammation**.
2. **Chronic obstructive pulmonary disease (COPD) exacerbations** commonly involve **worsening dyspnea**, **increased cough severity or frequency**, and **increased sputum amount or a change in sputum character**.
3. **Chronic obstructive pulmonary disease (COPD) exacerbations** are most often **triggered** by **respiratory infections (viral or bacterial)**, **smoking**, or **environmental exposures**, although **no trigger** may be identified.
4. **Chronic obstructive pulmonary disease (COPD) exacerbations** are **underreported** and are associated with **adverse outcomes**.

---

#### ‚úÖ True Statements ‚Äî Prevention of COPD Exacerbation
1. Preventing **chronic obstructive pulmonary disease (COPD) exacerbations** **improves quality of life**, **reduces health care costs**, **slows lung-function decline**, and **decreases mortality**.
2. Prevention strategies in **chronic obstructive pulmonary disease (COPD)** include **smoking cessation**, **pulmonary rehabilitation when appropriate**, **recommended immunizations**, and **proper inhaler technique and medication use**.
3. **Long-term azithromycin** or **roflumilast** prevents **future exacerbations** in **selected severe chronic obstructive pulmonary disease (COPD)** with a **history of frequent exacerbations**.

---

#### ‚úÖ True Statements ‚Äî Initial Assessment of COPD Exacerbation and Setting of Care
1. A **mild chronic obstructive pulmonary disease (COPD) exacerbation** can be treated with **short-acting bronchodilators alone**.
2. A **moderate chronic obstructive pulmonary disease (COPD) exacerbation** requires **antibiotics**, **glucocorticoids**, or **both**.
3. A **severe chronic obstructive pulmonary disease (COPD) exacerbation** requires **emergency department evaluation** or **hospitalization**.
4. **Hospitalization** for a **chronic obstructive pulmonary disease (COPD) exacerbation** is indicated with **respiratory distress** or **risk of respiratory distress**.
5. In a hospitalized **chronic obstructive pulmonary disease (COPD) exacerbation**, **chest radiography**, **ECG**, **complete blood count**, and **basic metabolic panel** help assess **alternative causes** and **comorbidities**.
6. **Pulse oximetry** should be performed to measure **oxygen saturation** in **chronic obstructive pulmonary disease (COPD) exacerbations**.
7. **Arterial blood gases** are recommended in **severe chronic obstructive pulmonary disease (COPD) exacerbations** to identify **hypercapnia** or **hypoxemia**.
8. **Sputum culture** is **not routinely indicated** in **chronic obstructive pulmonary disease (COPD) exacerbations** because it **rarely changes management**.
9. **Pulmonary embolism** should be **considered** as a **trigger** for a **chronic obstructive pulmonary disease (COPD) exacerbation**, especially when there is **poor response** to typical therapies.

---

#### ‚úÖ True Statements ‚Äî Therapeutic Management of COPD Exacerbation
1. The goals of managing a **chronic obstructive pulmonary disease (COPD) exacerbation** are to **relieve acute symptoms** and **prevent future exacerbations**.
2. **Supplemental oxygen** during a **chronic obstructive pulmonary disease (COPD) exacerbation** should target **SpO‚ÇÇ 88%‚Äì92%**.
3. **Noninvasive positive-pressure ventilation** is indicated in **chronic obstructive pulmonary disease (COPD) exacerbations** when adequate **oxygenation** or **ventilation** cannot be maintained.
4. **Intubation and mechanical ventilation** are indicated in **chronic obstructive pulmonary disease (COPD) exacerbations** when **noninvasive ventilation** is **not tolerated**, when **mental status is altered**, or when **hypercapnic or hypoxemic respiratory failure** worsens **despite noninvasive ventilation**.
5. **Short-acting Œ≤‚ÇÇ-agonists (SABAs)**, with or without **anticholinergic agents**, should be used to **relieve acute symptoms** in a **chronic obstructive pulmonary disease (COPD) exacerbation**.
6. **Oral glucocorticoids** during a **chronic obstructive pulmonary disease (COPD) exacerbation** **decrease treatment failure**, **shorten length of stay**, **reduce early relapse**, and **improve FEV‚ÇÅ and oxygenation**.
7. A **short course of oral prednisone 40 mg daily for 5 days** is **usually equivalent** to **longer**, **higher-dose**, or **intravenous** glucocorticoid regimens for a **chronic obstructive pulmonary disease (COPD) exacerbation**.
8. **Bacterial pathogens** in **chronic obstructive pulmonary disease (COPD) exacerbations** include **Streptococcus pneumoniae**, **Haemophilus influenzae**, **Moraxella catarrhalis**, and **Mycoplasma pneumoniae**.
9. **Antibiotics for 5‚Äì7 days** are recommended in **chronic obstructive pulmonary disease (COPD) exacerbations** that **require mechanical ventilation** (invasive or noninvasive) and in patients with **all three cardinal symptoms** (**dyspnea**, **increased sputum volume**, **increased sputum purulence**) or with **two symptoms** when **purulence** is present.
10. **Antibiotics plus oral glucocorticoids** reduce **treatment failure** in **mild to severe chronic obstructive pulmonary disease (COPD) exacerbations**.
11. **Smoking cessation** should be addressed during and after a **chronic obstructive pulmonary disease (COPD) exacerbation** to **prevent recurrence**.

---

## üóÇÔ∏è Supplemental Tables (HTML) + Derivations

### 1) Modified Medical Research Council (mMRC) Dyspnea Scale
<table>
  <caption><strong>Modified Medical Research Council Dyspnea Scale</strong></caption>
  <thead>
    <tr><th>Score</th><th>Description of Dyspnea</th><th>Severity</th></tr>
  </thead>
  <tbody>
    <tr><td>0</td><td>I only get breathless with strenuous exercise.</td><td>None</td></tr>
    <tr><td>1</td><td>I get short of breath when hurrying on level ground or walking up a slight hill.</td><td>Mild</td></tr>
    <tr><td>2</td><td>I walk slower than people of the same age on level ground because of breathlessness, or I have to stop for breath when walking at my own pace on level ground.</td><td>Moderate</td></tr>
    <tr><td>3</td><td>I stop for breath after walking approximately 100 m or after a few minutes on level ground.</td><td>Severe</td></tr>
    <tr><td>4</td><td>I am too breathless to leave the house or I am breathless when dressing or undressing.</td><td>Very severe</td></tr>
  </tbody>
</table>
<p><em>Adapted from Fletcher CM, Elmes PC, Fairbairn AS, et&nbsp;al. Br Med J. 1959;2:257. PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/13823475/">13823475</a>.</em></p>

#### ‚úÖ True Statements ‚Äî mMRC Dyspnea Scale
1. The **Modified Medical Research Council (mMRC) Dyspnea Scale** assigns **scores 0‚Äì4** to grade dyspnea severity.
2. An **mMRC score of 0** indicates **breathlessness only with strenuous exercise**.
3. An **mMRC score of 1** indicates **breathlessness when hurrying on level ground or walking up a slight hill**.
4. An **mMRC score of 2** indicates **slower walking than peers or the need to stop for breath at own pace on level ground**.
5. An **mMRC score of 3** indicates **stopping for breath after ~100 m or a few minutes on level ground**.
6. An **mMRC score of 4** indicates **too breathless to leave the house or breathless when dressing or undressing**.

---

### 2) COPD Assessment Test (CAT‚Ñ¢) ‚Äî Patient Self-Report Items
<table>
  <caption><strong>COPD Assessment Test (CAT‚Ñ¢) ‚Äî Symptom Items</strong></caption>
  <thead>
    <tr><th>Item</th><th>Response Scale</th></tr>
  </thead>
  <tbody>
    <tr><td>Cough frequency</td><td>0 (never cough) to 5 (cough all the time)</td></tr>
    <tr><td>Phlegm in chest</td><td>0 (no phlegm) to 5 (chest completely full of phlegm)</td></tr>
    <tr><td>Chest tightness</td><td>0 (no tightness) to 5 (very tight)</td></tr>
    <tr><td>Breathlessness walking uphill/stairs</td><td>0 (not breathless) to 5 (very breathless)</td></tr>
    <tr><td>Activity limitation at home</td><td>0 (not limited) to 5 (very limited)</td></tr>
    <tr><td>Confidence leaving home</td><td>0 (confident) to 5 (not at all confident)</td></tr>
    <tr><td>Sleep quality</td><td>0 (sleep soundly) to 5 (do not sleep soundly because of lung condition)</td></tr>
    <tr><td>Energy level</td><td>0 (lots of energy) to 5 (no energy at all)</td></tr>
  </tbody>
</table>
<p><em>Jones PW, Harding G, Berry P, et&nbsp;al. Eur Respir J. 2009;34:648‚Äì54. PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/19720809/">19720809</a>. Reproduced with permission of GOLD.</em></p>

#### ‚úÖ True Statements ‚Äî CAT Assessment
1. The **COPD Assessment Test (CAT)** comprises **eight patient-reported items** scored **0‚Äì5** each.
2. The **CAT total score ranges 0‚Äì40**, with **higher scores indicating worse symptoms**.
3. The **CAT** assesses **cough**, **phlegm**, **chest tightness**, **breathlessness with hills/stairs**, **activity limitation**, **confidence leaving home**, **sleep quality**, and **energy level**.

---

### 3) Classification of COPD Severity by GOLD Patient Category
<table>
  <caption><strong>Classification of COPD Severity by GOLD Patient Category</strong></caption>
  <thead>
    <tr><th>Patient Category</th><th>Characteristics</th><th>Exacerbations Per Year</th><th>CAT Score</th><th>mMRC Score</th></tr>
  </thead>
  <tbody>
    <tr><td>A</td><td>Low risk, fewer symptoms</td><td>‚â§1, no hospitalization</td><td>&lt;10</td><td>0‚Äì1</td></tr>
    <tr><td>B</td><td>Low risk, more symptoms</td><td>‚â§1, no hospitalization</td><td>‚â•10</td><td>‚â•2</td></tr>
    <tr><td>E</td><td>High risk</td><td>‚â•2 or ‚â•1 with hospitalization</td><td>Any</td><td>Any</td></tr>
  </tbody>
</table>
<p><em>Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2025 Report.</em></p>

#### ‚úÖ True Statements ‚Äî GOLD Patient Categories
1. **GOLD Category A** describes **low risk with fewer symptoms** and **‚â§1 exacerbation/year without hospitalization**, typically **CAT &lt;10** and **mMRC 0‚Äì1**.
2. **GOLD Category B** describes **low risk with more symptoms** and **‚â§1 exacerbation/year without hospitalization**, typically **CAT ‚â•10** and **mMRC ‚â•2**.
3. **GOLD Category E** describes **high risk** with **‚â•2 exacerbations/year or ‚â•1 with hospitalization**, with **any CAT** and **any mMRC** score accepted.

---

### 4) GOLD Grades and Severity of Airflow Obstruction in COPD
<table>
  <caption><strong>GOLD Grades and Severity of Airflow Obstruction in COPD</strong></caption>
  <thead>
    <tr><th>Category</th><th>Severity</th><th>Spirometry (Post-bronchodilator FEV‚ÇÅ)</th></tr>
  </thead>
  <tbody>
    <tr><td>GOLD 1</td><td>Mild</td><td>FEV‚ÇÅ ‚â•80% of predicted</td></tr>
    <tr><td>GOLD 2</td><td>Moderate</td><td>50% ‚â§ FEV‚ÇÅ &lt;80% of predicted</td></tr>
    <tr><td>GOLD 3</td><td>Severe</td><td>30% ‚â§ FEV‚ÇÅ &lt;50% of predicted</td></tr>
    <tr><td>GOLD 4</td><td>Very severe</td><td>FEV‚ÇÅ &lt;30% of predicted</td></tr>
  </tbody>
</table>
<p><em>GOLD = Global Initiative for Chronic Obstructive Lung Disease. Applies when FEV‚ÇÅ/FVC &lt;0.7.</em></p>

#### ‚úÖ True Statements ‚Äî GOLD Spirometric Grades
1. **GOLD 1 (mild)** airflow obstruction corresponds to **FEV‚ÇÅ ‚â•80% predicted** when **FEV‚ÇÅ/FVC &lt;0.7**.
2. **GOLD 2 (moderate)** airflow obstruction corresponds to **50% ‚â§ FEV‚ÇÅ &lt;80% predicted** when **FEV‚ÇÅ/FVC &lt;0.7**.
3. **GOLD 3 (severe)** airflow obstruction corresponds to **30% ‚â§ FEV‚ÇÅ &lt;50% predicted** when **FEV‚ÇÅ/FVC &lt;0.7**.
4. **GOLD 4 (very severe)** airflow obstruction corresponds to **FEV‚ÇÅ &lt;30% predicted** when **FEV‚ÇÅ/FVC &lt;0.7**.

---

### 5) Recommended Pharmacologic Management of COPD by GOLD Classification
<table>
  <caption><strong>Recommended Pharmacologic Management of COPD by GOLD Classification</strong></caption>
  <thead>
    <tr><th>Patient Group</th><th>Recommended Therapy</th><th>Alternative or Additional Therapy</th><th>Other Considerations</th></tr>
  </thead>
  <tbody>
    <tr>
      <td>A</td>
      <td>Short-acting bronchodilator <em>or</em> Long-acting bronchodilator</td>
      <td>Evaluate effect; continue, stop, or try alternative bronchodilator as appropriate</td>
      <td>All patients should receive bronchodilator therapy based on dyspnea; continue if symptomatic benefit</td>
    </tr>
    <tr>
      <td>B</td>
      <td>LABA + LAMA</td>
      <td>If LABA+LAMA not appropriate, choose one long-acting agent based on patient-perceived symptom relief</td>
      <td>Long-acting bronchodilators are superior to short-acting as-needed; no evidence favors one long-acting class over another for initial relief; comorbidities are common and should be addressed</td>
    </tr>
    <tr>
      <td>E</td>
      <td>LABA + LAMA <br/> or LABA + LAMA + ICS<sup>a</sup></td>
      <td>
        If exacerbations continue, consider: <br/>
        ‚Ä¢ **Roflumilast** (FEV‚ÇÅ &lt;50% predicted with chronic bronchitis, particularly with ‚â•2 exacerbations or ‚â•1 hospitalization in past year) <br/>
        ‚Ä¢ **Macrolide therapy** (best evidence: azithromycin) <br/>
        ‚Ä¢ **Dupilumab** (chronic bronchitis)<sup>a</sup>
      </td>
      <td>Patients with concomitant asthma should receive an **ICS**</td>
    </tr>
  </tbody>
</table>
<p><em>GOLD 2025 Report. LABA = long-acting Œ≤‚ÇÇ-agonist; LAMA = long-acting muscarinic antagonist; ICS = inhaled corticosteroid.</em><br/>
<sup>a</sup><em>Consider if blood eosinophils ‚â•300/¬µL (0.30 √ó 10‚Åπ/L).</em></p>

#### ‚úÖ True Statements ‚Äî GOLD Pharmacologic Management
1. **GOLD Group A** therapy for **COPD** is a **short-acting bronchodilator or a long-acting bronchodilator**, with ongoing evaluation for benefit.
2. **GOLD Group B** therapy for **COPD** is **LABA + LAMA**; if combination therapy is not appropriate, choose **one long-acting agent** based on **symptom relief**.
3. **GOLD Group E** therapy for **COPD** is **LABA + LAMA**, with consideration of **LABA + LAMA + ICS** when **eosinophils ‚â•300/¬µL** or when asthma features are present.
4. For **COPD** with **persistent exacerbations** despite guideline therapy, additional options include **roflumilast** (for **FEV‚ÇÅ &lt;50% with chronic bronchitis**), **long-term macrolide therapy** (best evidence for **azithromycin**), or **dupilumab** in **chronic bronchitis**.
5. **COPD** patients with **concomitant asthma** should **receive an inhaled corticosteroid** as part of therapy.

---

### 6) BODE Index to Estimate Prognosis of COPD
<table>
  <caption><strong>BODE Index to Estimate Prognosis of COPD</strong></caption>
  <thead>
    <tr><th>Parameter</th><th>Points Assigned</th></tr>
  </thead>
  <tbody>
    <tr><td>BMI &gt;21</td><td>0</td></tr>
    <tr><td>BMI ‚â§21</td><td>1</td></tr>
    <tr><td colspan="2"><em>Obstruction of Airflow: Post-bronchodilator FEV‚ÇÅ (% predicted)</em></td></tr>
    <tr><td>&gt;65%</td><td>0</td></tr>
    <tr><td>50%‚Äì64%</td><td>1</td></tr>
    <tr><td>36%‚Äì49%</td><td>2</td></tr>
    <tr><td>‚â§35%</td><td>3</td></tr>
    <tr><td colspan="2"><em>Dyspnea: mMRC Score</em></td></tr>
    <tr><td>0 or 1</td><td>0</td></tr>
    <tr><td>2</td><td>1</td></tr>
    <tr><td>3</td><td>2</td></tr>
    <tr><td>4</td><td>3</td></tr>
    <tr><td colspan="2"><em>Exercise Capacity: 6-Minute Walking Distance</em></td></tr>
    <tr><td>‚â•350 m</td><td>0</td></tr>
    <tr><td>250‚Äì349 m</td><td>1</td></tr>
    <tr><td>150‚Äì249 m</td><td>2</td></tr>
    <tr><td>‚â§149 m</td><td>3</td></tr>
  </tbody>
</table>
<p><em>Celli BR, Cote CG, Marin JM, et&nbsp;al. N Engl J Med. 2004;350:1007. PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/14999112/">14999112</a>. Approximate 4-year survival by total score: 0‚Äì2 points ‚âà80%; 3‚Äì4 points ‚âà67%; 5‚Äì6 points ‚âà57%; 7‚Äì10 points ‚âà18%.</em></p>

#### ‚úÖ True Statements ‚Äî BODE Index
1. The **BODE index** for **COPD** assigns points for **Body mass index**, **airflow Obstruction** (post-bronchodilator **FEV‚ÇÅ% predicted**), **Dyspnea** (mMRC), and **Exercise** capacity (6-minute walk).
2. In the **BODE index**, **lower BMI (‚â§21)**, **lower FEV‚ÇÅ% predicted**, **higher mMRC score**, and **shorter 6-minute walk distance** each contribute **more points** and **worse prognosis**.
3. **Higher total BODE scores** correspond to **lower 4-year survival** in **chronic obstructive pulmonary disease (COPD)**.

---

### üóÇÔ∏è Supplemental Table

<table>
  <caption><strong>Characteristics and Adverse Effects of COPD Treatments</strong></caption>
  <thead>
    <tr>
      <th>Class / Agent</th>
      <th>Adverse Effects</th>
      <th>Notes</th>
    </tr>
  </thead>
  <tbody>
    <!-- Bronchodilators -->
    <tr>
      <td colspan="3"><strong>Bronchodilators</strong></td>
    </tr>
    <tr>
      <td>Inhaled short-acting Œ≤<sub>2</sub>-agonists (albuterol, fenoterol, levalbuterol, metaproterenol, pirbuterol, terbutaline)</td>
      <td>Tachycardia and hypokalemia (usually dose dependent); generally well tolerated</td>
      <td>Generally used as needed for mild disease with few symptoms</td>
    </tr>
    <tr>
      <td>Inhaled short-acting anticholinergic agents (ipratropium)</td>
      <td>Dry mouth; mydriasis on eye contact; tachycardia; tremors; rarely acute narrow-angle glaucoma; safe across a wide dose range and clinical settings</td>
      <td>Generally used as needed for mild disease with few symptoms; avoid using both short- and long-acting anticholinergics together</td>
    </tr>
    <tr>
      <td>Inhaled long-acting anticholinergic agents (tiotropium, aclidinium, umeclidinium, glycopyrrolate)</td>
      <td>Dry mouth; mydriasis on eye contact; tachycardia; tremors; rarely acute narrow-angle glaucoma</td>
      <td>Not to be used with ipratropium; use when short-acting bronchodilators provide insufficient symptom control</td>
    </tr>
    <tr>
      <td>Inhaled long-acting Œ≤<sub>2</sub>-agonists (salmeterol, formoterol, arformoterol, indacaterol, olodaterol)</td>
      <td>Sympathomimetic symptoms (tremor, tachycardia); overdose can be fatal</td>
      <td>Use as maintenance therapy when short-acting bronchodilators are insufficient; not for treatment of COPD exacerbations or acute bronchospasm; do not use as monotherapy in patients with asthma</td>
    </tr>
    <tr>
      <td>Methylxanthines (theophylline, aminophylline; sustained and short-acting)</td>
      <td>Tachycardia, nausea, vomiting, disturbed sleep; narrow therapeutic index; overdose can be fatal with seizures and arrhythmias</td>
      <td>Used as maintenance therapy; generally only after long-acting bronchodilator treatment to provide additional symptomatic relief of exacerbations; may also improve respiratory muscle function</td>
    </tr>
    <tr>
      <td>Oral Œ≤<sub>2</sub>-agonists (albuterol, metaproterenol, terbutaline)</td>
      <td>Sympathomimetic symptoms such as tremor and tachycardia</td>
      <td>Used as maintenance therapy; rarely used due to adverse effects but may benefit patients who cannot use inhalers</td>
    </tr>
    <!-- Oral Phosphodiesterase-4 Inhibitor -->
    <tr>
      <td colspan="3"><strong>Oral Phosphodiesterase-4 Inhibitor</strong></td>
    </tr>
    <tr>
      <td>Roflumilast</td>
      <td>Diarrhea, nausea, backache, decreased appetite, dizziness</td>
      <td>Reduces risk for exacerbations in severe COPD with chronic bronchitis and a history of exacerbations; should not be used with methylxanthines due to potential toxicity</td>
    </tr>
    <!-- Anti-Inflammatory Agents -->
    <tr>
      <td colspan="3"><strong>Anti-Inflammatory Agents</strong></td>
    </tr>
    <tr>
      <td>Inhaled glucocorticoids (fluticasone, budesonide, mometasone, ciclesonide, beclomethasone, flunisolide)</td>
      <td>Dysphonia, skin bruising, oral candidiasis; rarely adverse effects of oral glucocorticoids</td>
      <td>Most effective in patients with a history of frequent exacerbations and when used with long-acting bronchodilators; consider in peripheral eosinophilia</td>
    </tr>
    <tr>
      <td>Oral glucocorticoids (prednisone, prednisolone)</td>
      <td>Skin bruising, adrenal suppression, glaucoma, osteoporosis, diabetes mellitus, systemic hypertension, pneumonia, cataracts, opportunistic infection, insomnia, mood disturbance</td>
      <td>Use for significant COPD exacerbations; avoid in stable COPD if possible to limit toxicity; consider inhaled glucocorticoids to facilitate weaning of systemic glucocorticoids</td>
    </tr>
    <tr>
      <td colspan="3"><strong>Combination Agents</strong></td>
    </tr>
    <tr>
      <td>Combined inhaled LABA + inhaled glucocorticoid (fluticasone‚Äìsalmeterol, budesonide‚Äìformoterol, mometasone‚Äìformoterol)</td>
      <td>Combined effects of both classes</td>
      <td></td>
    </tr>
    <tr>
      <td>Combined short-acting Œ≤<sub>2</sub>-agonist + short-acting anticholinergic (fenoterol‚Äìipratropium, albuterol‚Äìipratropium)</td>
      <td>Combined effects of both classes</td>
      <td>Generally used as needed for mild disease; avoid combining short- and long-acting anticholinergics; may be used as maintenance therapy if well controlled on this regimen and cost is a factor</td>
    </tr>
    <tr>
      <td>Combined inhaled glucocorticoid + ultra-LABA (fluticasone‚Äìvilanterol)</td>
      <td>Combined effects of both classes</td>
      <td>Not for acute bronchospasm; not preferred except in patients with asthma</td>
    </tr>
    <tr>
      <td>Combined LAMA + ultra-LABA (umeclidinium‚Äìvilanterol)</td>
      <td>Combined effects of both classes</td>
      <td>Not for acute bronchospasm; avoid combining short- and long-acting anticholinergics</td>
    </tr>
    <tr>
      <td>Combined LAMA + LABA (olodaterol‚Äìglycopyrrolate, indacaterol‚Äìglycopyrrolate, glycopyrrolate‚Äìformoterol, olodaterol‚Äìtiotropium)</td>
      <td>Combined effects of both classes</td>
      <td>Not for acute bronchospasm; avoid combining short- and long-acting anticholinergics</td>
    </tr>
    <tr>
      <td>Triple combination LAMA + LABA + inhaled glucocorticoid (fluticasone‚Äìumeclidinium‚Äìvilanterol)</td>
      <td>Combined effects of all three classes</td>
      <td>Not for acute bronchospasm; avoid combining short- and long-acting anticholinergics</td>
    </tr>
    <!-- Biologic Agents -->
    <tr>
      <td colspan="3"><strong>Biologic Agents</strong></td>
    </tr>
    <tr>
      <td>Dupilumab</td>
      <td>Hypersensitivity reactions; helminth infections</td>
      <td>Can be added to long-acting anticholinergic + LABA + inhaled glucocorticoid regimen for chronic bronchitis with eosinophil count ‚â•300/¬µL</td>
    </tr>
  </tbody>
</table>

### ‚úÖ True Statements ‚Äî COPD Treatments
1. **Inhaled short-acting Œ≤‚ÇÇ-agonists** may cause **tachycardia** and **hypokalemia**, are **dose dependent**, and are **generally well tolerated**.  
2. **Inhaled short-acting Œ≤‚ÇÇ-agonists** are **generally used as needed** for **mild COPD with few symptoms**.  
3. **Ipratropium** may cause **dry mouth**, **tachycardia**, **tremors**, and **mydriasis on eye contact**, and can **rarely trigger acute narrow-angle glaucoma**.  
4. **Ipratropium** is **generally used as needed** for **mild COPD**, and **should not be combined** with long-acting anticholinergics.  
5. **Long-acting anticholinergics** (e.g., tiotropium) can cause **dry mouth**, **tachycardia**, **tremors**, and **rare glaucoma**, and are **not to be used with ipratropium**.  
6. **Long-acting anticholinergics** are used in **COPD when short-acting bronchodilators are insufficient**.  
7. **Long-acting Œ≤‚ÇÇ-agonists** can cause **tremor** and **tachycardia**, and **overdose may be fatal**.  
8. **Long-acting Œ≤‚ÇÇ-agonists** are for **maintenance therapy in COPD**, are **not indicated for acute bronchospasm**, and **must not be used as monotherapy in asthma**.  
9. **Methylxanthines** (e.g., theophylline) may cause **tachycardia, nausea, vomiting, and disturbed sleep**, and have a **narrow therapeutic index**; **overdose can cause seizures and arrhythmias**.  
10. **Methylxanthines** are used as **maintenance therapy in COPD**, generally after long-acting bronchodilators, and may **improve respiratory muscle function**.  
11. **Oral Œ≤‚ÇÇ-agonists** cause **tremor** and **tachycardia**, are **rarely used** because of **side effects**, but may help patients who **cannot use inhalers**.  
12. **Roflumilast** can cause **diarrhea**, **nausea**, **backache**, **decreased appetite**, and **dizziness**.  
13. **Roflumilast** reduces **exacerbations** in **severe COPD with chronic bronchitis** and **should not be combined with methylxanthines**.  
14. **Inhaled glucocorticoids** can cause **dysphonia**, **skin bruising**, and **oral candidiasis**, and rarely **systemic glucocorticoid side effects**.  
15. **Inhaled glucocorticoids** are most effective in **COPD patients with frequent exacerbations** when **combined with long-acting bronchodilators**, and may be considered in **peripheral eosinophilia**.  
16. **Oral glucocorticoids** can cause **systemic toxicities** including **adrenal suppression**, **osteoporosis**, **diabetes**, **hypertension**, **pneumonia**, **cataracts**, and **mood disturbance**.  
17. **Oral glucocorticoids** are used in **COPD exacerbations** but should be **avoided in stable COPD**; **inhaled glucocorticoids** can help reduce systemic exposure.  
18. **Combination inhalers** (e.g., SABA + SAMA, LABA + ICS, triple therapy) have **class-specific combined effects**, but are **not for acute bronchospasm**, and duplication of **anticholinergics should be avoided**.  
19. **Dupilumab** may cause **hypersensitivity** and **helminth infections**, and can be **added in chronic bronchitis with eosinophil count ‚â•300/¬µL**.

### üí¨ Extra ‚Äî COPD Treatments
1. The **adverse effects** listed are **dose related** and reflect typical class pharmacology.  
4. The caution against **combining short- and long-acting anticholinergics** avoids **therapeutic duplication**.  
7. The **fatality risk** from long-acting Œ≤‚ÇÇ-agonist overdose reflects **sympathomimetic toxicity**.  
13. **Roflumilast** should not be combined with **methylxanthines** due to overlapping **phosphodiesterase inhibition toxicity**.  
18. Combination inhalers must be used carefully to **avoid duplicate exposure** (e.g., short + long anticholinergic).  
19. The **dupilumab eosinophil threshold (‚â•300/¬µL)** is derived from guideline-based biologic use criteria.  
